Is AZN or BBIO more undervalued in 2026?

CirclFi compares AstraZeneca PLC (AZN) and BridgeBio Pharma, Inc. (BBIO) using 13 institutional-grade valuation models. AZN has a Quality of Company score of 10.0/10 while BBIO scores 6.5/10.

Which is a better buy — AZN or BBIO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AZN and BBIO valuations compare?

AZN at $185.67 and BBIO at $66.26 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AZN vs BBIO Valuation Comparison 2026 — Intrinsic Value Analysis

AZN

Pharmaceutical Preparations

AstraZeneca PLC

Quality

10.0

out of 10

Value Trap

SAFE

Price

$185.67

Last close

Models

12/13

Active

BBIO

Pharmaceutical Preparations

BridgeBio Pharma, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$66.26

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	AZN Fair Value	AZN Upside	BBIO Fair Value	BBIO Upside
Bayesian DCF	Intrinsic	$121.19	-34.7%	$19.97	-69.9%
Earnings Power Value	Intrinsic	$74.38	-59.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$169.35	-8.8%	$63.52	-13.3%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AZN vs BBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AZN vs BBIO — Which Stock Is More Undervalued?

AZN scores higher with a 10.0/10 quality rating vs BBIO's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AstraZeneca PLC (AZN) and BridgeBio Pharma, Inc. (BBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AZN currently trades at $185.67 with a QOC of 10.0/10, while BBIO trades at $66.26 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).